RhumbLine Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $754K | Buy |
116,060
+34,216
| +42% | +$222K | ﹤0.01% | 2394 |
|
|
2025
Q1 | $649K | Buy |
81,844
+6,291
| +8% | +$49.9K | ﹤0.01% | 2397 |
|
|
2024
Q4 | $957K | Sell |
75,553
-1,747
| -2% | -$22.1K | ﹤0.01% | 2275 |
|
|
2024
Q3 | $1.08M | Sell |
77,300
-8,138
| -10% | -$113K | ﹤0.01% | 2233 |
|
|
2024
Q2 | $1.18M | Sell |
85,438
-4,289
| -5% | -$59.1K | ﹤0.01% | 2154 |
|
|
2024
Q1 | $1.48M | Buy |
89,727
+2,293
| +3% | +$37.9K | ﹤0.01% | 2056 |
|
|
2023
Q4 | $1.28M | Sell |
87,434
-1,769
| -2% | -$25.8K | ﹤0.01% | 2138 |
|
|
2023
Q3 | $1.09M | Buy |
89,203
+22,942
| +35% | +$281K | ﹤0.01% | 2154 |
|
|
2023
Q2 | $791K | Buy |
66,261
+22,265
| +51% | +$266K | ﹤0.01% | 2423 |
|
|
2023
Q1 | $588K | Buy |
43,996
+1,043
| +2% | +$13.9K | ﹤0.01% | 2374 |
|
|
2022
Q4 | $924K | Buy |
42,953
+711
| +2% | +$15.3K | ﹤0.01% | 2166 |
|
|
2022
Q3 | $846K | Buy |
42,242
+8,288
| +24% | +$166K | ﹤0.01% | 2233 |
|
|
2022
Q2 | $608K | Buy |
33,954
+14,546
| +75% | +$260K | ﹤0.01% | 2390 |
|
|
2022
Q1 | $193K | Buy |
+19,408
| New | +$193K | ﹤0.01% | 2765 |
|